title: Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo.
abstract: Human epidermal growth factor receptor 2 (HER2) has been found to be overexpressed in ~25% of invasive breast cancer and is significantly associated with a poor prognosis in breast cancer patients. The anthocyanins cyanidin-3-glucoside (C3G) and peonidin-3-glucoside have been identified as potential drugs for the therapy of HER2‑positive breast cancer. They have been used as supplements in targeted therapeutics and chemotherapeutics in Asia, however, the underlying mechanism remains to be elucidated. The aim of the present study was to investigate the synergism between C3G and trastuzumab (Trast). To address this question, the response to C3G, Trast and a combination of the two drugs, in three representative HER2‑positive cell lines was evaluated. The combination treatments induced apoptosis, inhibited cell growth and affected HER2 and its downstream signaling pathway in MDA‑MB‑453, BT474 and HCC1569 cells, and the effects were synergistic. The combination of 3CG and Trast inhibited tumor growth in an in vivo xenograft model. The data from the present study suggested that C3G exhibits potent antitumor activity when combined with Trast under the investigated conditions.
authors: Department of Scientific Research, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China.
authors: Weihua
authors: W
authors: Liu
authors: Department of Scientific Research, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China.
authors: Jinmei
authors: J
authors: Xu
authors: Department of Scientific Research, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China.
authors: Yilun
authors: Y
authors: Liu
authors: Department of Public Health, Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China.
authors: Xiaoping
authors: X
authors: Yu
authors: Department of Scientific Research, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China.
authors: Xi
authors: X
authors: Tang
authors: Department of Scientific Research, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China.
authors: Zhi
authors: Z
authors: Wang
authors: Administrative Office, Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China.
authors: Xin
authors: X
authors: Li
mesh_terms: D000818:Animals; D000872:Anthocyanins / Q000627:therapeutic use / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D004357:Drug Synergism; D005260:Female; D005960:Glucosides / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D007668:Kidney / Q000473:pathology; D008099:Liver / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013154:Spleen / Q000473:pathology; D014183:Transplantation, Heterologous; D000068878:Trastuzumab
chemical_list: D000872:Anthocyanins; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D005960:Glucosides; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D051057:Proto-Oncogene Proteins c-akt; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C462279:cyanidin-3-O-beta-glucopyranoside; C480521:peonidin 3-glucoside; C508053:ERBB2 protein, human